SCHEMBL397799

SCHEMBL397799

Nc1ncnc2c1ncn2[C@]1(Cl)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.53
ADORA2A P29274 3/20 0.53
SLC28A1 O00337 2/20 0.53
PI4KA P42356 2/20 0.53
PI4K2B Q8TCG2 2/20 0.53
PI4K2A Q9BTU6 2/20 0.53
PI4KB Q9UBF8 2/20 0.53
ADORA2B P29275 2/20 0.53
DPP4 P27487 1/20 0.53
MEN1 O00255 1/20 0.53
MAP3K7 O43318 1/20 0.53
SLC28A2 O43868 1/20 0.53
GAPDH P04406 1/20 0.53
MAPK1 P28482 1/20 0.53
ADORA1 P30542 1/20 0.53
STAT6 P42226 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
DOT1L Q8TEK3 1/20 0.53
SLC29A1 Q99808 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL23802568 0.94 ADORA1 (0.50) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL10365538 0.87 SLC29A1 (0.39) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL31062627 0.85 ADORA3 (0.55) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL481525 0.85 ADORA3 (0.55) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL5024893 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL454216 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
Water SCHEMBL27885621 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL23042807 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL1417403 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL27657118 0.84 ADORA3 (0.54) ADORA3ADORA2ASLC28A1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1639182-A Synthesis method of 5 '-deoxy-5' -chloroadenosine and 5 '-deoxy-5' -methylthioadenosine PFIZER (US) 2005-07-13 CN claimed
EP-1483279-A1 PROCESSES FOR THE SYNTHESIS OF 5'-DEOXY-5'-CHLOROADENOSINE AND 5'-DEOXY-5'-METHYLTHIOADENOSINE PFIZER INC. (US) 2004-12-08 EP claimed
US-20030181713-A1 Processes for the synthesis of chloroadenosine and methylthioadenosine SRIRANGAM JAYARAM KASTURI (US) 2003-09-25 US claimed
WO-2003074541-A1 PROCESSES FOR THE SYNTHESIS OF 5’-DEOXY-5’ CHLOROADENOSINE AND 5’-DEOXY-5’METHYLTHIOADENOSINE PFIZER INC. (US) 2003-09-12 WO claimed
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 US claimed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US claimed
JP-5255378-A None JP disclosed
JP-61171423-A None JP disclosed
US-12551475-B2 Methods and compositions for treating RNA viral infections MODEL MEDICINES, INC. (US) 2026-02-17 US disclosed
US-12516080-B2 Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-01-06 US disclosed
EP-4667008-A2 METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS Model Medicines, Inc. (US) 2025-12-24 EP disclosed
US-20250017936-A1 CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF PURDUE RESEARCH FOUNDATION 2025-01-16 US disclosed
EP-4436566-A1 CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF Purdue Research Foundation (US) 2024-10-02 EP disclosed
EP-0390112-A2 Selective adenosine receptor agents MERRELL PHARMACEUTICALS INC. (US) 1990-10-03 EP disclosed
EP-0390111-A2 Selective adenosine receptor compounds MERRELL DOW PHARMACEUTICALS INC. (US) 1990-10-03 EP disclosed
EP-0269574-A2 Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1988-06-01 EP disclosed
EP-0253962-A2 Use of adenosine derivatives as anti-dementia agents HOECHST JAPAN LIMITED (JP) 1988-01-27 EP disclosed
JP-S61171423-A DRUG FOR ALLEVIATING DENTAL CARIES AND PERIODONTOSIS ADVANCE RES & DEV CO LTD 1986-08-02 JP disclosed
CN-85108658-A N 6The manufacture method that replaces ribodesose adenyhomotype thing 1986-07-16 CN disclosed
US-4376116-A TREATMENT OF CYSTIC FIBROSIS AND PARASITIC INFECTIONS RESEARCH CORPORATION (US) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017936-A1 CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF NNMT, NAMPT, NNT ADORA3 3333/4885ADORA2A 3317/4885SLC28A1 35/4885
US-12551475-B2 Methods and compositions for treating RNA viral infections SARS1, EIF2AK2, SNRPE ADORA3 438/4885ADORA2A 913/4885SLC28A1 587/4885
US-20020177695-A1 Nucleic acid probes and methods NUDT1, NT5C3B, NT5C2 ADORA3 80/4885ADORA2A 229/4885SLC28A1 152/4885
US-20030181713-A1 Processes for the synthesis of chloroadenosine and methylthioadenosine MTAP, ADAR, NUDT1 ADORA3 80/4885ADORA2A 37/4885SLC28A1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.